Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical-stage pharmaceutical company developing novel therapeutics in metabolic diseases, focusing on non-alcoholic steatohepatitis (NASH), and oncology. Emphasis on these disease areas originates from our expertise with the fatty acid synthase enzyme (FASN) and its central role in multiple diseases. Our lead product candidate, TVB-2640, is an oral, highly potent, selective and reversible, first-in-class inhibitor of...
We are a clinical-stage pharmaceutical company developing novel therapeutics in metabolic diseases, focusing on non-alcoholic steatohepatitis (NASH), and oncology. Emphasis on these disease areas originates from our expertise with the fatty acid synthase enzyme (FASN) and its central role in multiple diseases. Our lead product candidate, TVB-2640, is an oral, highly potent, selective and reversible, first-in-class inhibitor of FASN.

List your booth number for exhibitions, ask us